Believing that the risk of autistic disorders in connection with Depakine was known to the laboratory, at least in 2005, and that consequently it had the duty to mention it in the notice, the Nanterre court condemned, Thursday, Sanofi to compensate up to 450,000 euros for a family whose daughter, exposed to Depakine in utero, was born with malformations.
The mother, followed for epileptic seizures, took this drug since 1982. In 2004, during her pregnancy, she took four tablets a day.
When she was seven months old, her daughter was hospitalized with bronchiolitis. An “overall delay in acquisitions” was then noted. Delays in psychomotor development were then observed throughout his childhood. In 2016, his parents took Sanofi to court.
letelegramme Fr Trans